TP53 and glaucoma: The ability of RG-7112 treatment to concurrently significantly increase p53 protein expression and significantly decrease MDM2 protein expression levels shows promise in targeting dysregulation of the p53-MDM2-ubiquitin-proteasomal system at the lamina cribrosa in the pathogenesis of glaucoma.